Related references
Note: Only part of the references are listed.Programmed cell death-ligand 1 assessment in urothelial carcinoma: prospect and limitation
Kyu Sang Lee et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2021)
The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma
Thomas Powles et al.
CANCER TREATMENT REVIEWS (2020)
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Y. Fradet et al.
ANNALS OF ONCOLOGY (2019)
Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays
Kristina Schwamborn et al.
VIRCHOWS ARCHIV (2019)
Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma
Magdalena Zajac et al.
DIAGNOSTIC PATHOLOGY (2019)
PD-L1 assessment in urothelial carcinoma: a practical approach
Markus Eckstein et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab
Markus Eckstein et al.
EUROPEAN JOURNAL OF CANCER (2019)
Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP)
Carol C. Cheung et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2019)
Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression
Maria Tretiakova et al.
MODERN PATHOLOGY (2018)
Share Paper
